Frazier Life Sciences Management L.P. Increases Stock Position in Maze Therapeutics, Inc. $MAZE

Frazier Life Sciences Management L.P. grew its position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 10.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,567,275 shares of the company’s stock after purchasing an additional 438,274 shares during the period. Maze Therapeutics makes up approximately 2.2% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its 12th biggest position. Frazier Life Sciences Management L.P. owned 0.10% of Maze Therapeutics worth $56,040,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in MAZE. Engineers Gate Manager LP bought a new position in Maze Therapeutics during the second quarter valued at approximately $125,000. Bank of America Corp DE boosted its position in shares of Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after acquiring an additional 1,455 shares during the last quarter. CW Advisors LLC purchased a new position in shares of Maze Therapeutics in the second quarter valued at $371,000. Virtus Investment Advisers LLC bought a new stake in Maze Therapeutics in the second quarter worth $85,000. Finally, Legal & General Group Plc raised its stake in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares in the last quarter.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $38.86 on Friday. The firm has a market capitalization of $1.87 billion and a P/E ratio of -1.86. Maze Therapeutics, Inc. has a 1-year low of $6.71 and a 1-year high of $43.29. The company’s 50-day moving average is $33.34 and its 200 day moving average is $21.93.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Guggenheim lifted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Wells Fargo & Company initiated coverage on Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. HC Wainwright upped their price objective on Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. lifted their target price on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, September 29th. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $41.88.

Insiders Place Their Bets

In other news, Director Richard H. Scheller sold 20,744 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.